Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure

Liu, Haiyang; Li, Suyan; Zhang, Zhengpei; Shen, Jie

doi:10.3892/etm.2017.5437

Cited by 8 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A third limitation was that we did not evaluate foveal OCT features with BCVA and peripheral nonperfusion. The relationship between vision and OCT features in the setting of macular edema, however, has been evaluated in previous publications 22,23 and was not the focus of this study. Third, the RVO population recruited into this study was required to have evidence of ischemia and to have persistent/recurrent ME; as such, our findings may not be applicable to the general population of those with RVO.…”

Section: Discussionmentioning

confidence: 90%

Ultra-Wide-Field Fluorescein Angiography–Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion

Wang

Falavarjani

Nittala

et al. 2018

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. The purpose of this study was to compare the use of central and montaged ultrawide-field fluorescein angiography (UWFFA) images for calculating the area of nonperfusion (NP) and ischemic index (ISI) in patients with retinal vein occlusion (RVO) and macular edema (ME) and to correlate these measurements with best-corrected visual acuity (BCVA) and central macular thickness (CMT).METHODS. Thirty eyes of 30 RVO patients with recurrent ME were enrolled. Baseline UWFA images were sent to the Doheny Image Reading Center for quantitative analysis by certified graders. The association between ISI from the various zones and BCVA and CMT was examined by Spearman rank correlation and compared. Generalized linear models (GLMs) were used to analyze associations between BCVA and disease status.RESULTS. The NP area and ISI for central and montaged images were not significantly different for any retinal zone. A modest but statistically significant negative linear correlation was observed between BCVA and ISI, ranging from r ¼ À0.3825 in the perimacular area (PMA) to r ¼ À0.584 in the far peripheral area (FPA). On GLM analysis, both PMA (b ¼ À1.059; 95% confidence interval: À1.74 to À0.378) and FPA (b ¼ À0.505; 95% confidence interval: À0.988 to À0.021) were significant independent predictors of BCVA. We found no correlation between ISI from the various zones and CMT in this cohort. CONCLUSIONS.Montaging of UWFFA images may not be required to adequately quantify and represent areas of NP in eyes with RVO. NP in both the PMA and peripheral retina appear relevant to visual function, highlighting the importance of evaluating the retinal periphery in these individuals.

show abstract

Section: Discussionmentioning

confidence: 90%

Ultra-Wide-Field Fluorescein Angiography–Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion

Wang

Falavarjani

Nittala

et al. 2018

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…After the initiation of treatment with ranibizumab, BCVA was recorded at 4,8,12,16,20,24,28,36, and 48 weeks.…”

Section: Measurement Of Treatment Outcomesmentioning

confidence: 99%

“…Excessive angiogenic growth factors such as vascular endothelial cell growth factor (VEGF) caused by hypoxia secondary to RVO, leads to vascular leakage and macular edema (ME). Loss of vision is attributed to the development of ME, which occurs due to high vascular permeability caused by breakdown of blood-retina barrier [ 1 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Narayanan

Kelkar²,

Abbas

et al. 2021

BMC Ophthalmol

View full text Add to dashboard Cite

Background Macular edema secondary to retinal vein occlusion (RVO) is an important cause of loss of vision. Intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) are the standard of care in this disease, as shown in numerous randomized controlled trials. The purpose of this study was to study the efficacy and safety of ranibizumab, an anti-VEGF agent, in the real-world setting. Methods This was 48 weeks, open-label, prospective, multicentre, observational study. Patients diagnosed with ME secondary to RVO were treated with IVI of Ranibizumab 0.5 mg in real-world conditions. Efficacy was measured by improvement seen in best-corrected visual acuity (BCVA) in terms of Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores and change in central retinal thickness (CRT) measured by optical coherence tomography. Results One hundred eyes of 100 patients (79 with branch retinal vein occlusion and 21 with central retinal vein occlusion) were recruited in the study. The mean (standard deviation, SD) BCVA was 52.8 (21.99) letters at baseline and 62.3 (24.40) letters at week 48. From baseline, there was a significant improvement in BCVA by 7.7 letters (p = 0.001) at 48 weeks. The mean (SD) of CRT was 479.9 (216.25) μm at baseline and it decreased significantly to 284.9 (171.35) μm at week 48 (p < 0.001). During the study period, the average number of intravitreal injections was 3.5 per patient. There was no report of endophthalmitis in any eye. Conclusions Ranibizumab is well tolerated and effective in treating macular edema secondary to RVO in real-world clinical settings. However, there is under-treatment compared to controlled clinical trials, and the gain in vision is sub-optimal with under-treatment. Trial registration Clinical Trials Registry - India: CTRI/2015/07/005985.

show abstract

“…[10] Liu et al discovered that external limiting membrane integrity is a prediction factor of visual function in CRVO-ME patients that have received ranibizumab injections. [11] However, SD-OCT assessment is still rarely to predict the visual acuity in CRVO-ME patients after conbercept therapy.…”

Section: Introductionmentioning

confidence: 99%

Predictors of Visual Recovery in Patients with Macular Edema Secondary to Central Retinal Occlusion After Treatment with Conbercept

Zhang

Hou

Cao

et al. 2021

Preprint

View full text Add to dashboard Cite

Background The use of Spectral domain optical coherence tomography (SD-OCT) to evaluate the predictors of visual acuity-recovery in patients treated with conbercept for macular edema (ME) secondary to central retinal vein occlusion (CRVO) has rarely been seen.We collected 24 CRVO-ME patients with different OCT measures at 6 months follow-up to identify the factors that are most strongly correlated with the best-corrected visual acuity (BCVA) post-treatment in CRVO-ME patients treated with conbercept Purpose To evaluate the effectiveness of intravitreal conbercept injections for the treatment of CRVO-ME and to determine the major predictors of best-corrected visual acuity (BCVA) post-treatment. Methods A retrospective study methodology was used. Twenty-four eyes from 24 patients with CRVO-ME were enrolled in the study. After an initial intravitreal injection of conbercept (0.5 mg/0.05 ml), monthly injections for up to 6 months were given following a 1 + PRN (pro re nata) regimen. Data collected at monthly intervals included measurements of the logMAR BCVA, central subfield thickness (CST), macular volume (MV), photoreceptor layer thickness (PLT), outer nuclear layer thickness (ONLT), and the disrupted ellipsoid zone (DEZ). The correlation between BCVA, before and after injections, and each of CST, MV, PLT, ONLT, DEZ was analyzed. Results The logMAR BCVA in months 3 and 6 post-injection was significantly improved relative to the baseline. In this same period the CST, MV, PLT, ONLT and DEZ were also significantly improved relative to the baseline. There was a negative correlation between PLT and logMAR BCVA at months 3 and 6 (r = -0.549, P < 0.001; r = -0.087, P < 0.001). Conclusion Intravitreal injection of conbercept is an effective treatment for CRVO-ME. With six months of follow-up, logMAR BCVA and CST, MV, PLT, ONLT, DEZ improved. PLT was negatively correlated with the visual function in CRVO-ME patients after conbercept treatment, which may be a predictor of vision recovery in patients with CRVO-ME.

show abstract

Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure

Cited by 8 publications

References 37 publications

Ultra-Wide-Field Fluorescein Angiography–Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion

Ultra-Wide-Field Fluorescein Angiography–Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Predictors of Visual Recovery in Patients with Macular Edema Secondary to Central Retinal Occlusion After Treatment with Conbercept

Contact Info

Product

Resources

About